Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Quidel — Investor Presentation (January 2014)
12 slides from Quidelortho's investor presentation, Jan 21, 2014
Slide 1: Investor Presentation
Exhibit 99.1 Investor Presentation Doug Bryant, President & CEO
Slide 2: Investor Presentation
Investor Presentatio n Doug Bryant, President & CEO
Slide 3: Company history (1979-2009)
Company Pathway 1999 receives clearance 2000 FluFDA 2009 marker A/B 1990 history First product 1980 company business (1979 1970 – 2009) to receive 3 1984 CLIA First waiver commercial for Strep product A, Helicobacter introduced: pylori, pregnancy and Influenza 1979 Quidel A+Bfounded 1985 FDA-cleared
Slide 4: Recent company history (2009-Present)
Recent AmpliVue 2009 molecular Hybrids Diagnostic 2010 BioHelix Acquires 2013 A+B FIA company 2011 2013 assays: development 2012 3 FDA history Influenza 2013 clearances begins (2009 FDAA+B clearance –2010 Present) and for NU Sofia hMPV for agreement 4assays: 2009 C. 2010 difficile 2013 Strep signed
Slide 5: Sofia from a customer perspective
From aAcustomer ?Currently oStrep oQualitative oRSV ?Assays oLegionella oVitamin ?Improved oFFN oPROM ?Objectively 5?Cellularinwireless Dmarketed development performance Quant hCG readperspective, result, capability Sofiarelative ohCG with products: many Sofia Quant to traditional is fail-safe oInfl
Slide 6: Sofia is compelling: over half-way to 10,000 placements by end of 2014
We know Sofia is compelling, because we are already over half-way to our goal of 10,000 placements by the end of 2014 6
Slide 7: Sofia wireless connectivity
Sofia’s Router 7user viasends wireless emailresult orconnectivity FTPto site cloudUser the allows access message health data classified systems through by and a web Sofia public portal serial health number authorities Once per to monitor day, Quidel results Cloud in near-real collects time messages
Slide 8: Molecular innovations in the near term
In theCLEARED FDA near term, our ASSAYS innovations FDA CLEARED in the MDxASSAYS space will be equally compelling 8 Quidel Molecular LYRA REAL-TIME PCR Quidel Molecular AMPLIVUE Quidel Molecular SAVANNA
Slide 9: Financial and balance sheet overview
Quidel $200 (in Actual Cash Total $10.2 Long 269.2 Stockholder’s 5.2 Leverage 217.7 FY2013 0.1 $ million, Assets 200820092010201120122013E9 and Term (12 Financial estimated Cash Ratio months Debt percent Equity Equivalents Overview annual ended grossDecember revenue margin $128.1 estimate in $164.3
Slide 10: Operating cost structure: R&D and S&M investment
2013 $23.7 (in increase $ million; Expected $26.3 in resources $30.7 percentage Operating Range: in Q2 ofCost $34-35 2013. sales Structure in 10 Range: white)$20.9 $30-32$-$5 Annual $23.3 Investment: $24.0 $10 $15 $25.8 $20 S&M$30.3 $25 (in$30 Range: $ million) $35 $33-34 $40Note: 2008A2009A2010A201
Slide 11: Increased regulatory output in 2013
In 2013, company’s 8411 0 2Submissions 2009 FDA AmpliVue 6Quidel 10 2010 achievement 12 delivered 2008 Group HSV 2011 consists 12 510(k) of internal submissions goals,towhich the FDA mayresulting vary fromin time 9 510(k) to time, clearances and areSource: not indicative Companyof future data throug
Slide 12: Quidel's 2014 milestones
••Quidel’s •Sofia10,000 FDA milestones Receive instrument CLIA Quantitative clearance for assay Commercialization submission ofplacements waiver and 2014 for 12 Strepgenerating development: of A,hCG, C. difficile commercialization 32manufactured additional RSV and revenue and hCG Vitamin GBS of D pr